[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335875-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-335875-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","breaking-barriers-a-future-perspective-on-glioblastoma-therapy-with-mrna-based-immunotherapies-and-oncolytic-viruses","Breaking Barriers - A Future Perspective on Glioblastoma Therapy with mRNA-Based Immunotherapies and Oncolytic Viruses","","mRNA-based immunotherapies using oncolytic virus genomes offer significant potential for glioblastoma (GBM), a highly aggressive neurological cancer. The work emphasizes mRNA platforms to reduce risks of live-virus cancer therapy while enabling researchers to customize oncolytic virus genome sequences for precise targeting of cancer cells. By combining structural-protein segments or regions with oncolytic activity, the approach may improve efficacy and limit effects on non-cancerous cells. It highlights advances on Zika virus (ZIKV) for GBM and the need to clarify mechanisms to support ZIKV-based clinical trials targeting GBM patients, suggesting a potential paradigm shift.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/breaking-barriers-a-future-perspective-on-glioblastoma-therapy-with-mrna-based-immunotherapies-and-oncolytic-viruses/335875/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/breaking-barriers-a-future-perspective-on-glioblastoma-therapy-with-mrna-based-immunotherapies-and-oncolytic-viruses/335875.png","ImageObject",300,407,{"name":42,"@type":43},"Logic","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"Why is Zika virus (ZIKV) highlighted for GBM, and what is still required?","Question",{"text":63,"@type":64},"ZIKV is described as having oncolytic properties against GBM and is presented as opening new therapeutic avenues; however, a comprehensive understanding of its underlying mechanisms is needed to enable ZIKV-based clinical trials.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},335875,1790209391,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,103,107,112,115,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":99,"doc_module":4,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},7,"Healthcare",40,"healthcare",{"id":104,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":105,"slug":106},8,30,"research-report",{"id":108,"doc_module":4,"doc_module_name":25,"category_name":109,"show_sort_weight":110,"slug":111},9,"Religion & Spirituality",20,"religion-spirituality",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":113,"show_sort_weight":110,"slug":114},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":55,"slug":117},"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":104,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":137,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Perspective  \nBreaking Barriers: A Future Perspective on Glioblastoma Therapy with mRNA-Based Immunotherapies and Oncolytic Viruses  \nAlexandro Guterres 1,2, *, Paulo Niemeyer Soares Filho 3 and Vivaldo Moura-Neto 3,4  \nCitation: Guterres, A.; Filho, P.N.S.;  \nMoura-Neto, V. Breaking Barriers: A Future Perspective on Glioblastoma Therapy with mRNA-Based Immunotherapies and Oncolytic Viruses. Vaccines 2024, 12, 61 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)vaccines12010061  \nAcademic Editor: Fabio Grizzi  \nReceived: 29 November 2023  \nRevised: 21 December 2023  \nAccepted: 28 December 2023  \nPublished: 8 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Laboratório de Hantaviroses e Rickettsioses, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro 21040-360, RJ, Brazil  \n2 Laboratório de Tecnologia Imunológica, Instituto de Tecnologia em Imunobiológicos, Vice-Diretoria de Desenvolvimento Tecnológico, Bio-Manguinhos, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro 21040-360, RJ, Brazil  \n3 Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro 20231-092, RJ, Brazil;  \n[niemeyer@globo.com](niemeyer@globo.com) (P.N.S.F.); [vivaldomouraneto@gmail.com](vivaldomouraneto@gmail.com) (V.M.-N.)  \n4 Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-590, RJ, Brazil * Correspondence: [guterres_rj@yahoo.com.br](guterres_rj@yahoo.com.br)  \nAbstract: The use of mRNA-based immunotherapies that leverage the genomes of oncolytic viruses holds significant promise in addressing glioblastoma (GBM), an exceptionally aggressive neurological tumor. We explore the significance of mRNA-based platforms in the area of immunotherapy, introducing an innovative approach to mitigate the risks associated with the use of live viruses in cancer treatment. The ability to customize oncolytic virus genome sequences enables researchers to precisely target specific cancer cells, either through viral genome segments containing structural proteins or through a combination of regions with oncolytic potential. This strategy may enhance treatment effectiveness while minimizing unintended impacts on non-cancerous cells. A notable case highlighted here pertains to advanced findings regarding the application of the Zika virus (ZIKV) in GBM treatment. ZIKV, a member of the family Flaviviridae, shows oncolytic properties against GBM, opening novel therapeutic avenues. We explore intensive investigations of glioblastoma stem cells, recognized as key drivers in GBM initiation, progression, and resistance to therapy. However, a comprehensive elucidation of ZIKV’s underlying mechanisms is imperative to pave the way for ZIKV-based clinical trials targeting GBM patients. This investigation into harnessing the potential of oncolytic-virus genomes for mRNA-based immunotherapies underscores its noteworthy implications, potentially paving the way for a paradigm shift in cancer treatment strategies.  \nKeywords: molecular therapy; mRNA-based immunotherapy; oncolytic virus; glioblastoma; cancer treatment; Zika virus; glioblastoma stem cells; oncolytic virotherapy  \n1. Introduction  \nBrain tumors are a critical area of study within the realm of medical research and neuro-oncology. These neoplastic growths, originating from abnormal cell proliferation in the brain or its adjacent tissues, encompass a wide spectrum of biological behaviorsand clinical manifestations [1] . These tumors can be broadly classified into two categories: primary brain tumors, which develop directly from brain cells, and secondary brain tumors, also known as metastatic tumors, which origin","cbCaik8MyjKjdKvZ","https://ap.wps.com/l/cbCaik8MyjKjdKvZ","pdf",991137,15,"English","# Introduction\n## Glioblastoma (GBM) overview\n## Challenges in treatment","[{\"question\":\"Why is Zika virus (ZIKV) highlighted for GBM, and what is still required?\",\"answer\":\"ZIKV is described as having oncolytic properties against GBM and is presented as opening new therapeutic avenues; however, a comprehensive understanding of its underlying mechanisms is needed to enable ZIKV-based clinical trials.\"}]","Breaking Barriers - A Future Perspective on Glioblastoma Therapy with mRNA-Based Immunotherapies and Oncolytic Viruses | PDF",1790012660,38]